News

Chevron (NYSE:CVX) reported second-quarter 2026 earnings of $12.1 billion, or $6.11 per share, as higher upstream realizations, production volumes and refining margins lifted results. Adjusted earnings were $12 billion, or $6.06 per share, while cash flow from operations excluding working capital to

APPS heads into fiscal Q1 2027 earnings with expected double-digit revenue growth, powered by ODS, AGP, AI tools and global partnerships.

Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.

Ultra Clean heads into Q2 earnings with AI-driven chip demand and rising fab activity, but a premium valuation and stiff competition raise the bar for execution.

Investing.com -- Short sellers have increased their positions in SpaceX before two major events next week: the company's first earnings report as a public company and the release of hundreds of millions of locked-up shares.

Markel Group's Q2 results reflect stronger underwriting and investment income, but weaker performance in the Industrial and Financial segments hurt earnings.

Unusual Machines heads into Q2 results with surging revenue expectations as defense demand, new capacity and strategic investments shape the outlook.

GDDY tops Q2 earnings and revenue estimates as growth across both segments, rising ARPU, and accelerating Airo adoption support results and guidance.

RDDT tops Q2 earnings and revenue estimates as ad demand, pricing and user growth fuel monetization, with Q3 guidance pointing to continued momentum.

FRSH heads into Q2 earnings with estimated revenue growth of 14.1%, backed by EX momentum and cost discipline as CX growth stays muted

Wall Street offered mixed views on Apple’s outlook after earnings, while Stocktwits retail traders largely shrugged off the selloff and stayed bullish.

GLW's AI optics growth, stronger cash flow and rising estimates support upside, but a premium valuation leaves little room for execution misses.

SATL heads into Q2 earnings with revenue seen more than doubling as defense deals, recurring imagery sales and cash-flow risks shape the outlook.

DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.

Astera Labs Q2 earnings are likely to gain from strong AI connectivity momentum, but margin pressure, rich valuation, and rising competition could keep investors cautious.

OVBC's second-quarter 2026 earnings face pressure from higher credit loss provisions despite stronger net interest income and continued loan growth.

LPLA's Q2 results benefit from strong revenue and advisory asset growth while boosting its buyback authorization. Yet, higher expenses partly offset the gains.

IR beats Q2 earnings and revenue estimates, raises its 2026 sales outlook and reports stronger orders, cash flow and M&A momentum.

Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories about which company holds the upper hand heading into a pivotal summer of reports and pricing resets.

EMR heads into Q3 fiscal 2026 earnings with expected sales and EPS growth as automation strength and the AspenTech buyout face cost pressures.

CBOE's Q2 earnings beat estimates. Record Options revenues, broad-based growth and stronger margins drove a raised 2026 revenue outlook.

Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.

WESCO tops Q2 earnings and revenue estimates as data center sales surge, backlog hits a record, and management raises its 2026 outlook.

SpaceX (SPCX) just got some very good news. The U.S. Space Force awarded the company two task orders worth a combined $1.6 billion to launch 18 Falcon 9 rockets carrying military satellites. The news was announced on July 29. Every launch will lift off from Vandenberg Space Force Base in ...

Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.

American Express’s results for Q2 were in line with Wall Street’s revenue expectations and slightly exceeded earnings estimates, but the market reacted negatively. Management pointed to strong momentum in premium product adoption, especially the Platinum Card refresh, as a key factor driving double-digit revenue growth. CEO Stephen Squeri highlighted that both new customer acquisition and greater engagement from existing cardholders contributed to the acceleration in spend, particularly in trave

AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.

Reddit Shares Sink Despite Earnings Beat as AI Search Threat Takes Center Stage

(Bloomberg) -- Short sellers have piled into SpaceX at a rapid pace ahead of two major milestones next week: the company’s first earnings report as a public company and the release of hundreds of millions of locked-up shares.Most Read from BloombergSingapore's Gated Island for the Rich Is Marred by Decayed HomesAnthropic AI Models Hacked Three Organizations During TestsMicrosoft’s $450 Billion Jump Is Biggest in Stock Market HistoryChip Stocks Post Biggest Advance Since April 2025: Markets WrapM

Moby summary of Linde plc's Q2 2026 earnings call